Drug intelligence / Profile preview

Redenser

Development stage: Unknown
Lead developer: La Pristine Bioceuticals
Modality: Small Molecules, Peptides
Administration: Topical

Overview

Redenser (specifically Redenser+ Serum) is a topical hair growth formulation developed by La Pristine Bioceuticals. It is a combination product containing several active complexes: Redensyl, Procapil, Capixyl, and Aminexil. Redensyl targets hair follicle stem cells to initiate the anagen phase; Procapil inhibits 5-alpha reductase and improves scalp microcirculation; Capixyl stimulates extracellular matrix proteins to improve follicle anchoring; and Aminexil prevents the hardening of collagen (perifollicular fibrosis) which can lead to premature hair loss. It is primarily used for the treatment of androgenetic alopecia and telogen effluvium.

Brand names: RedenserRedenser+ Serum
Other names: Redenser Plus

Targets

Steroidogenesis (Steroidogenic enzymes)

Beyond the preview

Go deeper on Redenser.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Redenser.

Explore the full profile